Table 1 Baseline characteristics
Intervention (n = 101) | Control (n = 100) | P-value | |
|---|---|---|---|
Age, years | 72 (66–80) | 73 (66–79) | 0.99 |
Women (%) | 27.7 | 30.0 | 0.72 |
Smoking (%) | 4.0 | 6.0 | 0.51 |
Self-reported healtha | 70 (50–85) | 70 (50–80) | 0.70 |
Prior cardiovascular diseaseb | 38.6 | 42.0 | 0.63 |
HbA1c, mmol/mol | 58 (50–70) | 57 (51–65) | 0.36 |
Weight, kilograms | 85 (75–97) | 86 (76–97) | 1.0 |
Waist, centimeters | 103 (95–111) | 105 (96–112) | 0.55 |
Systolic blood pressure, mmHg | 128 (120–133) | 134 (124–145) | <0.001 |
Diastolic blood pressure, mmHg | 70 (65–80) | 76 (70–82) | 0.005 |
Cholesterol, mmol/L | 3.7 (3.4–4.0) | 4.1 (3.6–4.6) | <0.001 |
LDL-C, mmol/L | 1.9 (1.5–2.0) | 2.1 (1.6–2.5) | <0.001 |
HDL-C, mmol/L | 1.20 (0.98–1.39) | 1.18 (0.97–1.48) | 0.88 |
Triglycerides, mmol/L | 1.4 (1.0–1.9) | 1.5 (1.2–2.2) | 0.06 |
Study, ACSc (%) | 64.4 | 47.0 | 0.01 |
No lipid lowering treatment (%) | 9.9 | 12.0 | 0.63 |
Simvastatin (%) | 47.5 | 54.0 | 0.36 |
Atorvastatin (%) | 36.6 | 32.0 | 0.49 |
Other lipid lowering strategyd (%) | 5.9 | 1.0 | 0.06 |